Group items matching

in title, tags, annotations or url

December 15, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and "protected time" (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity.

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.

The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Pre-Market Approval (PMA)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.

This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects should have relevance to the mission of NIDA and where feasible should address NIDAs international scientific priority areas(http://www.drugabuse.gov/international/research-priorities). While the priorities will change from year to year, in FY15 priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation, and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with co-morbid disorders); the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact. The NIH R03 activity code supports discrete, well-defined projects that realistically can be completed in two years and that require limited levels of funding. The R03 activity code supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving andthe drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and (b) pre-trial feasibility testing for prevention services and systems research. It is expected that research conducted via this R34 mechanism will consist of early stage efficacy, effectiveness or services research that will provide intervention pilot and/or feasibility data that is a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This R34 FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols; rather, any development work must be imbedded within a pilot/feasibility study.Of particular interest are prevention interventions targeting the healthcare system.

This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and (b) pre-trial feasibility testing for prevention services and systems research

The purpose of this Funding Opportunity Announcement (FOA) is to support New Investigators in the biomedical, behavioral, and social sciences who are in the early stages of establishing independent careers in tobacco regulatory research. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Applicants are encouraged to conduct projects that ultimately have potential to inform regulations on tobacco product manufacturing, distribution, and marketing. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31.

This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects should have relevance to the mission of NIDA and where feasible should address NIDA's international scientific priority areas (http://www.drugabuse.gov/international/research-priorities). While the priorities will change from year to year, in FY15 priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation, and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with co-morbid disorders); the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact.

The purpose of this FOA is to provide support for applications that focus on data replication and the scalability of novel, targeted addiction treatments. Consistent with an experimental therapeutics approach, studies that would fall under the R33 (Phase II) would include studies with theory-derived targets (based on putative mechanisms of ATOD) and clearly defined hypotheses about how the proposed treatment directed at changing the target relates to clinical outcomes. In addition, studies that include preliminary efficacy with respect to target engagement and validation (i.e., data to establish the relation between target and symptom reduction and functional outcomes) are essential to the Phase II arm (R33). Studies of novel treatments include, but are not limited to behavioral, pharmacological, biologics-based, cognitive, device-based, interpersonal, physiological, or combined approaches. This FOA provides support for replication studies of addiction treatment across 2 or more settings. Specifically, this phase will focus on clinical trials that apply the target in a treatment setting (testing, refinement, and/or adaptation) to evaluate the efficacy and replicability of larger trials. Ultimately, the goal of this FOA is to replicate findings of mechanisms and processes underlying treatments or replication of strategies into novel intervention approaches that can be efficiently tested and replicated for their promise to address substance use disorder outcomes. Furthermore, these studies build on data that have been demonstrated with sufficient signal of target engagement from an analogous R21-like study to justify the proposed R33 trials.

Studies of novel treatments include, but are not limited to behavioral, pharmacological, physiological, learning- and device-based treatment approaches. This FOA provides support for up to two years (Phase I; R21) for protocol development, target identification and studies to confirm target engagement (i.e., link targets with tangible outcomes); followed by up to 3 years of support (Phase II; R33) for replication studies of addiction treatment across 2 or more settings. Specifically, this latter phase will focus on clinical trials that apply the target in a treatment setting (development, refinement, and/or adaptation) to evaluate the feasibility of conducting a larger trial.

This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug abuse research on HIV/AIDS. This FOA, AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug abuse and HIV/AIDS that can be carried out in a short period of time with limited resources. Applications under this FOA are welcomed from all areas of HIV/AIDS research that NIDA supports.

The purpose of this FOA is to solicit applications to examine the impact of behavioral interventions within the context of states plans for use of the SAMHSA Opioid STR grant funds authorized under the 21st Century Cures Act. Applications are encouraged for studies that examine the impact of interventions such as mindfulness meditation, cognitive behavioral therapy, or multi-disciplinary rehabilitation for primary or secondary prevention for opioid use disorder (OUD) or as an adjunct to medication assisted treatment (MAT) of OUD. Applications that emphasize treatment of the comorbidity of OUD and chronic pain are of particular interest.

The American Psychological Foundation provides financial support for innovative research and programs that enhance the power of psychology to elevate the human condition and advance human potential, both today and for generations to come. As part of this mission, APF is accepting applications for its APF Trauma Psychology Grant. Through the annual program, a single grant of up to $3,000 will be awarded in support innovative work aimed at alleviating trauma. To be eligible, applicants must be an early-career psychologist (no more than ten years postdoctoral); be affiliated with a nonprofit charitable, educational, or scientific institution, or governmental entity operating exclusively for charitable and educational purposes; have a demonstrated knowledge of trauma and trauma research; have demonstrated competence and capacity to execute the proposed work; and, if human participants are involved, have IRB approval from his/her host institution before funding can be awarded.

NCIPC is seeking research proposals focused on rigorously evaluating previously or currently implemented federal, state, local, tribal or organizational policies for impacts on multiple forms of violence, including child abuse and neglect, youth violence, intimate partner violence, sexual violence and/or suicide. The proposed research should evaluate the impact of a selected policy on reducing rates of at least two of these violence outcomes. The proposed research must focus on a policy that has not yet been rigorously evaluated. Applicants are encouraged to assess the impact of the policy on as many violence outcomes that is feasible as well as risk and protective factors that are common to multiple forms of violence. The proposed research will add to the limited evidence base regarding the impact of policies on preventing multiple forms of violence by rigorously evaluating federal, state, local, or organizational policy approaches.

Founded in 1972, the Tourette Association of America (formerly known as the Tourette Syndrome Association) has emerged as the premier national nonprofit organization working to make life better for all people affected by Tourette and tic disorders. The association advances its work by raising public awareness and fostering social acceptance; working to advance scientific understanding, treatment options, and care; educating professionals to better serve the needs of children, adults, and families challenged by Tourette and tic disorders; advocating for public policies and services that promote positive school, work, and social environments; providing help, hope, and a supportive community across the nation; and empowering its community to deal with the complexities of this spectrum of disorders. To that end, grants of up to $150,000 over two years will be awarded for basic and clinical studies on all aspects of Tourette syndrome. To be eligible, investigators are required to have an advanced degree such as a Ph.D., M.D. or equivalent or be allied professionals with advanced degrees such as R.N.s, Drs. of O.T., social workers, and related fields. Investigators from nonprofit and for-profit organizations can apply.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIGMS R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To this end, this funding opportunity announcement (FOA) encourages the development of innovative educational activities for pre-kindergarten to grade 12 (P-12), pre-service and in-service teachers (Teachers) and students from underserved communities with a focus on Courses for Skills Development, Research Experiences, Mentoring Activities, Curriculum or Methods Development and Outreach. Information on current SEPA projects can be found at: https://www.nigms.nih.gov/Research/crcb/sepa/Pages/default.aspx and http://nihsepa.org. Applicants are strongly encouraged to consult with the SEPA Scientific/Research Contact to be advised on the appropriateness of the intended P-12 STEM or ISE project for SEPA program objectives and the priorities of the NIGMS.

The goal of this project is to begin building a pipeline of victim service professionals that will serve American Indian /Alaska Native victims in locations that are often remote and where positions are often hard to fill. This program will work to identify students in relevant disciplines (e.g., sociology, social work, psychology, etc.) to serve in victim service positions either at BIA or in tribally based victim service programs. Eligible applicants will include tribal colleges and universities (individually or as a consortium), non-tribal colleges and universities that are located close to American Indian/Alaska Native communities, or any other organization with connections to both tribes and educational institutions that educate students pursuing degrees in fields relevant to victim services. It will be up to the applicant to create and propose a program including structural and administrative make-up. However, the applicant will identify students interested in serving in victim service positions in Indian Country or Alaska Native locations, handle the administrative aspects of the project (including setting internship requirements, addressing privacy issues associated with students interning in direct service positions etc.), and work directly with either BIA or a local tribally based victim service program to place students in internship or practicum experiences for credit or pay.

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.